Differential regulation of 6- and 7-Transmembrane helix variants of μ-opioid receptor in response to morphine stimulation

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Convertino, Marino ^a   Samoshkin, Alexander ^b   Viet, Chi T ^c   Gauthier, Josee ^d   Fraine, Steven P Li ^e   Sharif Naeini, Reza ^e   Schmidt, Brian L ^c   Maixner, William ^d   Diatchenko, Luda ^b   Dokholyan, Nikolay V ^a,d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CYCLIC AMP; MEMBRANE PROTEIN; MORPHINE; MU OPIATE RECEPTOR; POTASSIUM ION; PROTEIN VARIANT; ISOPROTEIN; NARCOTIC ANALGESIC AGENT;

ARTICLE; CALCIUM CELL LEVEL; CELL ACTIVITY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; POTASSIUM CONDUCTANCE; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; DRUG EFFECTS; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION;

ANALGESICS, OPIOID; HUMANS; MODELS, MOLECULAR; MORPHINE; PROTEIN CONFORMATION; PROTEIN ISOFORMS; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 84953281797     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142826     Document Type: Article

References (54)

1. Rowlingson JC, Murphy TM. Chronic Pain. In: Miller RD, editor. Anesthesia. Churchill Livingstone: Philadelphia, 2000. pp 7351-2379.
2. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, et al. (1996) Loss of morphineinduced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature 383: 819-823.
3. Sora I, Elmer G, Funada M, Pieper J, Li X-F, Hall FS, et al. (2001) μ Opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo μ receptor reserve. Neuropsychopharmacology 25: 41-54.
4. Uhl GR, Sora I, Wang ZJ (1999) The mu opiate receptor as a candidate gene for pain: Polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci USA 96: 7752-7755.
5. Reisine T, Pasternak GW. Opioid analgesics and antagonists. In: Gilman G, editor. The Pharmacological Basis of Therapeutics. McGraw-Hill: New York, 1996. pp. 521-555.
6. Crain SM, Shen KF (2000) Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 84: 121-131.
7. Serohijos AWR, Yin SY, Ding F, Gauthier J, Gibson DG, Maixner W, et al. (2011) Structural Basis for mu-Opioid Receptor Binding and Activation. Structure 19: 1683-1690. doi: 10.1016/j.str.2011.08.003
8. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, et al. (2011) Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 477: 549-555. doi: 10.1038/nature10361
9. Oldham WM, Hamm HE (2008) Heterotrimeric G protein activation by G-protein-coupled receptors. Nat Rev Mol Cell Biol 9: 60-71.
10. Waldhoer M, Bartlett SE, Whistler JL (2004) Opioid Receptors. Annu Rev Biochem 73: 953-990.
11. Zhang J, Ferguson SS, Barak LS, Bodduluri SR, Laporte SA, Law PY, et al. (1998) Role for G proteincoupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci USA 95: 7157-7162.
12. Whistler JL, Zastrow von M (1998) Morphine-Activated opioid receptors elude desensitization by betaarrestin. Proc Natl Acad Sci USA 95: 9914-9919.
13. Bohn LM, Dykstra LA, Lefkowitz RJ, Caron MG, Barak LS (2004) Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol 66: 106-112.
14. Groer CE, Schmid CL, Jaeger AM, Bohn LM (2011) Agonist-directed Interactions with Specific -Arrestins Determine -Opioid Receptor Trafficking, Ubiquitination, and Dephosphorylation. J Biol Chem 286: 31731-31741. doi: 10.1074/jbc.M111.248310
15. Shabalina SA, Zaykin DV, Gris P, Ogurtsov AY, Gauthier J, Shibata K, et al. (2009) Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum Mol Gen 18: 1037-1051. doi: 10.1093/hmg/ddn439
16. Gris P, Gauthier J, Cheng P, Gibson DG, Gris D, Laur O, et al. (2010) A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism. Mol Pain 6: 33. doi: 10.1186/1744-8069-6-33
17. Convertino M, Samoshkin A, Gauthier J, Gold MS, Maixner W, Dokholyan NV, et al. (2014) μ-Opioid receptor 6-Transmembrane isoform: A potential therapeutic target for new effective opioids. Prog Neuropsychopharmacol Biol Psychiatry S0278-5846(14):00235-8.
18. Samoshkin A, Convertino M, Viet CT, Wieskopf JS, Marcovitz J, Patel P, et al. (2015) Structural and functional interaction between six transmembrane μ-opioid receptor isoform and β2-Adrenoreceptors. Submitted to Scientific Reports.
19. Samoshkin A, Viet CT, Convertino M, Maixner W, Dokholyan NV, Schmidt B, et al. Structural and functional interaction between 6TM MOR isoform and β2 adrenoreceptor. International Narcotics Research Conference 2014, Montreal, Quebec, Canada, July 13-18, 2014.
20. Dokholyan NV, Buldyrev SV, Stanley HE, Shakhnovich EI (1998) Discrete molecular dynamics studies of the folding of a protein-like model. Fold Des 3: 577-587.
21. Shirvanyants D, Ding F, Tsao D, Ramachandran S, Dokholyan NV (2012) Discrete Molecular Dynamics: An Efficient And Versatile Simulation Method For Fine Protein Characterization. J Phys Chem B 116: 8375-8382. doi: 10.1021/jp2114576
22. Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, et al. (2012) Crystal structure of the mu-opioid receptor bound to a morphinan antagonist. Nature 485: 321-U170. doi: 10.1038/nature10954
23. Ding F, Yin SY, Dokholyan NV (2010) Rapid Flexible Docking Using a Stochastic Rotamer Library of Ligands. J Chem Inf Model 50: 1623-1632. doi: 10.1021/ci100218t
24. Ding F, Dokholyan NV (2013) Incorporating Backbone Flexibility in MedusaDock Improves Ligand-Binding Pose Prediction in the CSAR2011 Docking Benchmark. J Chem Inf Model 53: 1871-1879. doi: 10.1021/ci300478y
25. Shim J, Coop A, Mackerell AD (2013) Molecular Details of the Activation of the micro Opioid Receptor. J Phys Chem B. 117: 7907-7917. doi: 10.1021/jp404238n
26. Yin S, Biedermannova L, Vondrasek J, Dokholyan NV (2008) MedusaScore: An accurate force fieldbased scoring function for virtual drug screening. J Chem Inf Model 48: 1656-1662. doi: 10.1021/ci8001167
27. Majumdar S, Grinnell S, Le Rouzic V, Burgman M, Polikar L, Ansonoff M, et al. (2011) Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad Sci USA 108: 19778-83. doi: 10.1073/pnas.1115231108
28. Majumdar S, Subrath J, Le Rouzic V, Polikar L, Burgman M, Nagakura K, et al. (2012) Synthesis and Evaluation of Aryl-Naloxamide Opiate Analgesics Targeting Truncated Exon 11-Associated μ Opioid Receptor (MOR-1) Splice Variants. J Med Chem 55: 6352-62. doi: 10.1021/jm300305c
29. Mignat C, Wille U, Ziegler A (1995) Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci 56: 793-799.
30. Dror RO, Arlow DH, Maragakis P, Mildorf TJ, Pan AC, Xu H, et al. (2011) Activation mechanism of the β2-Adrenergic receptor. Proc Natl Acad Sci USA 108: 18684-18689. doi: 10.1073/pnas.1110499108
31. Miao Y, Nichols SE, Gasper PM, Metzger VT, McCammon JA (2013) Activation and dynamic network of the M2 muscarinic receptor. Proc Natl Acad Sci USA 110: 10982-10987. doi: 10.1073/pnas. 1309755110
32. Eadie WT, Dryard D, James FE, Roos M, Sadoulet B. Amsterdam: Statistical Methods in Experimental Physics; 1971.
33. Inturrisi CE (2002) Clinical pharmacology of opioids for pain. Clin J Pain 18: S3-S13.
34. Lambert DG, Atcheson R, Hirst RA, Rowbotham DJ (1993) Effects of morphine and its metabolites on opiate receptor binding, cAMP formation and [3H]noradrenaline release from SH-SY5Y cells. Biochem Pharmacol 46: 1145-1150.
35. Eckhardt K, Nevo I, Levy R, Mikus G, Eichelbaum M, Vogel Z. (2000) Morphine-related metabolites differentially activate adenylyl cyclase isozymes after acute and chronic administration. FEBS Lett 470: 309-314.
36. Gharagozlou P, Demirci H, David Clark J, Lameh J (2003) Activity of opioid ligands in cells expressing cloned mu opioid receptors. BMC Pharmacol 3: 1.
37. Schroeder JE, McCleskey EW (1993) Inhibition of Ca2+ currents by a mu-opioid in a defined subset of rat sensory neurons. J Neurosci 13: 867-873.
38. Mihara S, North RA (2012) Opioids increase potassium conductance in submucous neurones of guinea-pig caecum by activating δ-receptors. BMC Pharmacol 88: 315-322.
39. Hayashi T, Su T-P (2007) Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca (2+) signaling and cell survival. Cell 131: 596-610.
40. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307: 1625-1630.
41. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
42. Lazaridis T, Karplus M (2000) Effective energy functions for protein structure prediction. Curr Opin Struct Biol 10: 139-145.
43. Andersen HC (1980) Molecular dynamics simulations at constant pressure and/or temperature. J Chem Phys 72: 2384.
44. Kota P, Ding F, Ramachandran S, Dokholyan NV (2011) Gaia: automated quality assessment of protein structure models. Bioinformatics 27: 2209-2215. doi: 10.1093/bioinformatics/btr374
45. Hess B, Kutzner C, van der Spoel D, Lindahl E (2008) GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4: 435-447.
46. Brooks BR, Brooks CL III, Mackerell AD Jr., Nilsson L, Petrella RJ, Roux B, et al. (2009) CHARMM: The biomolecular simulation program. J Comput Chem 30: 1545-1614. doi: 10.1002/jcc.21287
47. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 926.
48. Klauda JB, Venable RM, Freites JA, O'Connor JW, Tobias DJ, Mondragon-Ramirez C, et al. (2010) Update of the CHARMM all-Atom additive force field for lipids: validation on six lipid types. J Phys Chem B 114: 7830-7843. doi: 10.1021/jp101759q
49. Zoete V, Cuendet MA, Grosdidier A, Michielin O (2011) SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem 32: 2359-2368. doi: 10.1002/jcc.21816
50. Darden T, Perera L, Li L, Pedersen L (1999) New tricks for modelers from the crystallography toolkit: the particle mesh Ewald algorithm and its use in nucleic acid simulations. Structure 7: R55-R60.
51. Hess B, Bekker H, Berendsen HJ, Fraaije JG (1997) LINCS: a linear constraint solver for molecular simulations. J Comput Chem 18: 1463-1472.
52. Parrinello M (1981) Polymorphic transitions in single crystals: A new molecular dynamics method. J Appl Phys 52: 7182.
53. HooverW(1985) Canonical dynamics: Equilibrium phase-space distributions. Phys Rev, A 31: 1695-1697.
54. Kleywegt GJ, Harris MR, Zou J, Taylor TC, Wahlby A, Jones TA. (2004) The Uppsala Electron-Density Server. Acta Cryst D 60: 2240-2249.